The ideal number of drugs needed and treatment duration are crucial issues in the management of multidrug resistant tuberculosis (MDRTB). Thus, we read with interest the Article by the Collaborative Group for the MetaAnalysis of Individual Patient Data in MDRTB treatment-2017, 1 the results of which support our proposal, 2 from 2015, to classify antituberculosis drugs on the basis of their toxicity, and sterilising or bactericidal activity.
The findings provide compel ling evidence on the use of fluoroquinolones (levofloxacin or moxifloxacin), plus linezolid and bedaquiline as the base for the initial treatment of tuberculosis strains with rifampicin resistance or multidrug resistance. 1 However, we believe that had these drugs been used from the start, some of the findings of the metaanalysis, 1 namely the optimal number of drugs needed to treat the cases (five) and treatment duration (18-20 months), would need to be refined. Both results were obtained because most of the drugs included in the regimens that had been evaluated by the meta analysis have no effect on treatment outcomes, 1 and many show poor or nil bactericidal and sterilising activity. [2] [3] [4] Two or three susceptible drugs, with good bactericidal and sterilising activity, is known to be enough to treat almost all cases of tuberculosis, even in individuals with MDRTB. 5 Moreover, treatment duration could be reduced to 9-12 months if two or three sterilising drugs are included in the regimen. 2,3 Given that levofloxa cin or moxifloxacin, linezolid, and bedaquiline have good bactericidal and sterilising profiles, 2,4 these three drugs, administered for 9-12 months, should theoretically be enough to cure rifampicinresistant or MDRTB. 6 In cases of fluoroquinolone resistance, fluoroquinolone could be replaced by clofazimine or delamanid, as both have good sterilising activity. 2, 6 We agree that clinical trials are needed to ascertain the optimal combination and treatment duration (because using only the required number of drugs would lower the toxicity and price of regimens) and to improve treatment adherence. We declare no competing interests.
